Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $13 | $11 | $8 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $14 | $13 | $11 | $8 |
| Revenue | $2 | $2 | $1 | $1 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| % Growth | 33.2% | 58.3% | 69.6% | – |
| Operating Cash Flow | $1 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | $0 | $0 | $0 |